Allergy Diagnostics Market Size, Share, and Industry Analysis, By Product (Instruments [Immunoassay Analyzers, Luminometers, and Others], and Reagents & Consumables), By Type (In-vivo and In-vitro), By Setting (Rapid and Point-of-care), By Allergen (Inhaled Allergens, Food Allergens, Drug Allergens, and Others), By End-user (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast, 2026-2034

The global allergy diagnostics market size was valued at USD 7.14 billion in 2025. The market is projected to grow from USD 8.02 billion in 2026 to USD 20.46 billion by 2034, exhibiting a CAGR of 12.41% during the forecast period.

The allergy diagnostics market is expected to rise significantly during the forecast period. Allergy diagnostics refers to the methods and tests used to identify and confirm allergic reactions and determine the specific substances (allergens) responsible for those reactions. These tests can include skin prick tests, blood tests, and challenge tests.

Increased incidence of allergies such as food allergies, allergic rhinitis, asthma, and atopic dermatitis globally is fueling demand for accurate diagnostic tools.

• For instance, as per the data provided by the Global Atopic Dermatitis Atlas (GADA) 2022 report published in October 2022, about 223 million people were living with atopic dermatitis worldwide in 2022.

Furthermore, the rising regulatory approvals and launches for allergy diagnosis products are further augmenting market growth. 

Allergy Diagnostics Market Driver

High Burden of Allergic Conditions Has Been Fueling Demand for Advanced Allergy Diagnostics, thereby Driving Market Growth 

The high burden of allergic conditions such as asthma, allergic rhinitis, eczema, and food allergies has considerably contributed to the growth of the global allergy diagnostics market. As allergies become more prevalent, it increases the demand for accurate diagnostics to identify triggers and manage symptoms. Moreover, these conditions impose a considerable health burden on affected individuals, often resulting in frequent healthcare visits for accurate diagnosis and specialized treatment. 

• For instance, as per the data provided by the Centers for Disease Control and Prevention (CDC) in July 2024, approximately 24.9 million individuals in the U.S. were diagnosed with asthma in 2021.

Furthermore, the rising awareness about early diagnosis of allergic conditions and the development of novel diagnostic tools are some of the additional factors supplementing market growth.

Percentage of Adults with Diagnosed Allergic Conditions, U.S., 2021

• As per the data provided by the Centers for Disease Control and Prevention (CDC) in January 2023, around 25.7% adult population in the U.S. had seasonal allergies in 2021. 

Allergy Diagnostics Market Restraint

Limited Awareness About Allergic Conditions Impeding Market Growth

The lack of awareness about allergic diseases significantly hampers the growth of the allergy diagnostic market. Many individuals remain unaware of the symptoms and severity of allergies, leading to underdiagnosis and delayed treatment. 

• For example, common symptoms such as nasal congestion, headaches, or skin rashes are often mistaken for other conditions, such as colds or skin infections, causing patients to overlook the need for specialized allergy testing. 

Moreover, in many regions, limited public knowledge results in fewer people seeking medical advice or diagnostic services for allergies, thereby reducing market demand for advanced testing solutions. 

• For example, as per the that provided by the Times of India in August 2023, there is a lack of knowledge about early diagnosis of allergic conditions in India.

This gap in awareness also affects healthcare providers, who may not prioritize allergy diagnosis due to insufficient training or understanding of allergy-related health issues. Consequently, without widespread recognition of allergic diseases and the availability of diagnostic options, the market faces stagnation, preventing the development and adoption of innovative testing methodologies that could improve patient outcomes.

Allergy Diagnostics Market Opportunity

Expansion of Healthcare Infrastructure and Rising Market Players' Focus on Receiving Funding Creates New Opportunities for Market Growth

The increasing focus of market players on securing funding for the development and launch of advanced allergy diagnosis products generates significant growth opportunities within the allergy diagnostic market.

• For instance, in October 2024, ATANIS Biotech secured new funding to facilitate the launch of its FAST-PASE allergy diagnostic test. This capital infusion enabled ATANIS to accelerate the commercialization of its mast cell activation test, which aimed to offer a safer and highly accurate alternative to traditional in vivo allergy diagnostics. The funding round was led by Spectrum Moonshot Fund, a Swiss family-backed investment entity focused on high-growth technology ventures, with support from experienced allergy industry investors.

Furthermore, the opening of new hospitals and diagnostic laboratories equipped with cutting-edge diagnostic tools in developing countries is fostering increased adoption of allergy testing. This trend is complemented by substantial investments from both government and private sectors in healthcare infrastructure, emphasizing the development of advanced diagnostic laboratories and specialized clinics. Collectively, these factors are creating favorable conditions for market growth and increased demand for allergy diagnostic services.

Key Insights

The report covers the following key insights:

• Prevalence of Allergic Conditions - by Key Countries/Regions, 2023/2024
• New Product Launches, by Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Impact of Tariffs on the Market

Segmentation

Analysis by Product

Based on product, the allergy diagnostics market is divided into instruments and reagents & consumables. The instruments segment is further sub-segmented into immunoassay analyzers, luminometers, and others. The reagents & consumables segment is anticipated to grow significantly from 2025-2032, owing to the increasing launch of allergy diagnostic kits. 

• For instance, in August 2023, Gold Standard Diagnostics announced the launch of the DNAllergen real-time PCR kits. This new product line completed its allergen testing offer with the molecular method.

Analysis by Type

Based on type, the allergy diagnostics market is segmented into in-vivo and in-vitro. The in-vitro segment is projected to grow at a substantial CAGR during the forecast period. The increasing regulatory approvals for in-vitro diagnostics augment segmental growth during the forecast period.

• For instance, in August 2022, Thermo Fisher Scientific Inc. announced that the U.S. Food & Drug Administration (FDA) had cleared ImmunoCAP Specific IgE (sIgE) allergen components for diagnosing wheat and sesame allergies for in vitro use.

Analysis by Setting

Based on setting, the allergy diagnostics market is segmented into rapid and point-of-care. The point-of-care segment is expected to grow at a noteworthy CAGR from 2025-2032, owing to increasing regulatory approvals for point-of-care allergy diagnostic systems.

• For instance, in June 2024, Kenota Health received the U.S. Food & Drug Administration (FDA) clearance for a CLIA Waiver for the point-of-care allergy test system.

Analysis by Allergen

On the basis of allergens, the allergy diagnostics market is segregated into inhaled allergens, food allergens, drug allergens, and others. The food allergens segment is anticipated to grow notably during the forecast period. The high burden of food allergy cases across the globe enhances segmental growth. 

• For instance, as per the data provided by Genentech, Inc. in March 2025, around 3.4 million children and 13.6 million adults in the U.S. were diagnosed with IgE-mediated food allergies in 2024.

Analysis by End-user

Based on end-user, the market is categorized into hospitals & clinics, diagnostic laboratories, and others. The hospitals and clinics segment is anticipated to grow significantly from 2025-2032. The rising number of allergic diseases, including asthma, rhinitis, and food allergies, is a significant factor pushing demand for allergy diagnostics, and hospitals are often the first point of contact for patients experiencing these issues. These factors drive hospitals & clinics' segmental growth.

• For example, as per the data provided by the American Lung Association in July 2024, approximately 44.2 million Americans were diagnosed with asthma in 2022.

Furthermore, investment in healthcare infrastructure and the opening of new hospitals to meet the growing demand for allergy diagnostics augment segmental growth throughout the forecast period.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a major share of the global allergy diagnostics market in 2024 and is expected to grow at a significant CAGR from 2025-2032, owing to increasing regulatory approvals of novel allergy diagnosis test kits and devices.

• For example, in October 2024, ALK, a global research-focused pharmaceutical company specializing in allergy prevention, diagnosis, and treatment, announced the U.S. Food & Drug Administration (FDA) approval for a new line of ALK allergy skin testing devices and well trays. This new range includes the AccuTest-1, AccuTest-8, and AccuTest-10 allergy skin testing devices, along with the 48-well and 60-well allergen trays for allergy testing and diagnosis.

Moreover, the high burden of allergic conditions requiring efficient diagnosis with novel diagnostic devices is one of the additional factors enhancing the market growth in this region. 

The allergy diagnostics market in Asia Pacific is expected to grow moderately throughout the forecast period. The increasing launch of novel allergy testing methods for the diagnosis of several allergic conditions is expected to fuel the market growth in this region.

• For example, in May 2023, Metropolis Healthcare unveiled a new testing platform utilizing component-resolved diagnostics (CRD) to aid India's population in diagnosing various allergy types. This fourth-generation allergy testing technology incorporates artificial intelligence (AI) to assist clinicians in making informed clinical decisions and optimizing treatment strategies for allergic diseases.

Key Players Covered

The global allergy diagnostics market consists of companies such as Thermo Fisher Scientific Inc., CANON MEDICAL SYSTEMS CORPORATION, Medline Industries, LP, bioMérieux, and Siemens Healthineers AG, among other players. The report includes the profiles of the following key players:

• Thermo Fisher Scientific Inc. (U.S.)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Medline Industries, LP. (U.S.)
• Henry Schein, Inc. (U.S.)
• Eurofins Viracor, LLC (U.S.)
• bioMérieux (France)
• Omega Diagnostics Ltd (England)
• R-Biopharm (Germany)
• Siemens Healthineers AG (Germany)

Key Industry Developments

• In April 2025, Beckman Coulter, Inc. launched the Next-Generation Basophil Activation Test (BAT) for research purposes only, designed to analyze allergies more effectively without exposing individuals to potentially harmful allergens.
• In October 2024, researchers at the University of Bern and Bern University Hospital developed a new test that simplifies the diagnosis of allergies.
• In July 2024, MADx and labors.at formed a strategic partnership to facilitate the analysis of patient samples using MADx's advanced ALEX allergy testing platform.
• In May 2023, Dr. Dang's Lab introduced Allergynius Dx, an AI-powered, innovative molecular allergy diagnostic test based on microarray technology, intended to provide reports that assist patients and doctors in making informed allergy management decisions.